This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Avid Radiopharmaceuticals: The Venture Debt Question
Rhodes-Kropf, Matthew; Leamon, AnnCase HBS-809086-EEntrepreneurshipThe CEO of a promising biotech company must decide how to respond to the macro-economic slump of late 2008. He had planned to pursue an aggressive schedule moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the market. This involved expanding the firm's facilities and headcount and he planned to fund this by taking venture debt. Although clinical trial data is extremely encouraging, questions ...Starting at €8.20
-
The Impact of Waves in Venture Capital and Private Equity, Module Note for Instructors
Rhodes-Kropf, MatthewTeaching Note HBS-814084-EEntrepreneurshipStarting at €0.00
-
VCPE Strategy Vignettes I, II, and 2012, Teaching Note
Rhodes-Kropf, Matthew; Burbank, NathanielTeaching Note HBS-814086-EEntrepreneurshipTeaching Note for 811043, 811054, and 812073.Starting at €0.00
-
Partners Group: Ain't No Mountain High Enough
Lietz, Nori Gerardo; Andrade, RicardoCase HBS-217035-EEntrepreneurshipPartners Group ("PG"), a Swiss based PE manager, initiated a series of strategic shifts and evolved from a predominately fund-of-funds manager into a large, multi-asset class PE firm focused on direct investments. PG was the first PE firm to go public in 2006. A number of large US based private equity firms followed to create a new category of firms; public private equity firms (PPEs). PG's results were superlative (565% since inception total r...Starting at €8.20
-
NextView Ventures
Tango, Jo; Lietz, Nori GerardoCase HBS-821031-EEntrepreneurshipDavid Beisel, Rob Go, and Lee Hower are non-partners at different-and-established venture capital (VC) firms. They decide to leave their positions to start a new seed-stage VC firm. The case covers the genesis of the firm, the formulation of its strategy and operations, and the founders' fundraising efforts. A key decision the case protagonists must make is whether to partner with two very successful entrepreneurs, who propose a merger with Nex...Starting at €8.20
-
Iris Running Crane: December 2009
Rhodes-Kropf, Matthew; Lerner, Josh; Leamon, AnnCase HBS-810073-EEntrepreneurshipIris Running Crane, an MBA candidate, must choose among three different job offers in private equity. One is with a top-tier megafund buyout operation; the second with a geographically focused mid-market fund; and the third with a one-time top-tier fund that is trying to reposition itself as a turnaround expert, starting with its own portfolio. Iris must consider the advantages and drawbacks of each position, and how each will help her achieve he...Starting at €8.20
-
Investcorp and the Moneybookers Bid
Rhodes-Kropf, Matthew; Knoop, Carin-Isabel; Lietz, Nori GerardoCase HBS-811013-EEntrepreneurshipIn January 2007, Hazem Ben-Gacem, managing director and co-head of Investcorp Technology Partners (ITP), needs to decide what to bid at an auction for Moneybookers Limited, one of the top three e-payment solution providers in Europe. However, approximately 70% of Moneybookers revenues were related to transactions from online gaming sites (down from 100% in 2002). Although the thesis was that e-commerce transactions would soon make up a much large...Starting at €8.20
-
Avid Radiopharmaceuticals and Lighthouse Capital Partners, Teaching Note
Rhodes-Kropf, Matthew; Leamon, AnnTeaching Note HBS-812066-EEntrepreneurshipTeaching Note for 810054.Starting at €0.00
-
Investcorp and the Moneybookers Bid, Teaching Note
Rhodes-Kropf, Matthew; Lobb, AnnelenaTeaching Note HBS-814093-EEntrepreneurshipTeaching Note for 811013.Starting at €0.00
-
Avid Radiopharmaceuticals and Lighthouse Capital Partners
Rhodes-Kropf, Matthew; Leamon, AnnCase HBS-810054-EEntrepreneurshipIn fall 2008, a venture lender must decide whether to make a loan to Avid, a small but promising venture-backed life sciences firm. In reviewing her proposal, Cristy Barnes considers the company's characteristics and how they differ from a typical investment. At the same time, the CEO and the venture capitalist are exploring the true costs and benefits of taking the loan, particularly in the uncertain economic climate of the time.Starting at €8.20